Keros Therapeutics (KROS) Common Equity (2019 - 2026)
Keros Therapeutics' Common Equity was $262.32 million in Q2 2026, down 62.9% from $706.73 million a year earlier.
Powered by 
Analysis
Keros Therapeutics (KROS) Common Equity (2019 - 2026) Analysis & Trends
At the end of FY2025, Common Equity at Keros Therapeutics came in at $303.13 million, down 47.0% from FY2024.
- Common Equity shows a five-year compound annual growth rate of 3.0% (FY2020 to FY2025).
- In earlier years, Common Equity was $571.55 million in FY2024 (+72.0%), $332.21 million in FY2023 (+19.7%), $277.42 million in FY2022 (+14.1%) and $243.17 million in FY2021 (-7.1%).
- The Q2 2026 figure marks the lowest quarterly Common Equity since Q3 2022.
- Compared with a year earlier, Common Equity was higher in five of the last seven quarters, with growth averaging 29.0%.
- The best year-over-year quarter for Common Equity over five years was Q3 2024 (growth of 80.1%); the worst was Q2 2026 (a decline of 62.9%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 40.27 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 81.53 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | -4.58 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 44.95 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 51.81 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 14.35 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 13.04 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 89.30 Bn |
| 10 | Keros Therapeutics | 185.02 Mn | -900.96 Mn | - | 279.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 279.10 Mn |
| Jun 30, 2026 | 262.32 Mn |
| Mar 31, 2026 | 285.63 Mn |
| Dec 31, 2025 | 303.13 Mn |
| Sep 30, 2025 | 703.58 Mn |
| Jun 30, 2025 | 706.73 Mn |
| Mar 31, 2025 | 728.87 Mn |
| Dec 31, 2024 | 571.55 Mn |
| Sep 30, 2024 | 532.84 Mn |
| Jun 30, 2024 | 420.92 Mn |
| Mar 31, 2024 | 453.95 Mn |
| Dec 31, 2023 | 332.21 Mn |
| Sep 30, 2023 | 295.84 Mn |
| Jun 30, 2023 | 326.26 Mn |
| Mar 31, 2023 | 354.98 Mn |
| Dec 31, 2022 | 277.42 Mn |
| Sep 30, 2022 | 241.03 Mn |
| Jun 30, 2022 | 211.21 Mn |
| Mar 31, 2022 | 223.49 Mn |
| Dec 31, 2021 | 243.17 Mn |
API Access
Keros Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=KROS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "KROS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=KROS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();